Business
Medicure announces ANDA collaboration with Apicore
Medicure announces ANDA collaboration with Apicore Medicure announces ANDA collabo...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure announces ANDA collaboration with Apicore\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntaj{\nTEXT-ALIGN: JUSTIFY\n}\n\n\n\n\n\n\nMedicure announces ANDA collaboration with Apicore\nCanada NewsWire\nWINNIPEG, Jan. 6, 2016\n\n\n\nWINNIPEG, Jan. 6, 2016 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a specialty pharmaceutical company, is pleased to announce that the Company has initiated the development of a high-value cardiovascular generic drug. The project is a collaboration between Medicure International, Inc. (a wholly owned subsidiary of Medicure Inc.) and Apicore US LLC (together with its affiliates \"Apicore\"), a leading-edge manufacturer of generic active pharmaceutical ingredients (\"API's\").  \n\nThe collaborative project is focused on the development of an intravenous abbreviated New Drug Application (\"ANDA\") drug product for an acute cardiovascular indication.  Medicure and Apicore have entered into an exclusive product supply and development agreement under which Medicure holds all commercial rights. The companies anticipate filing the ANDA with the U.S. Food and Drug Administration by the end of 2016. \n\nMedicure, through its affiliates, is a minority shareholder in Apicore and holds an option to acquire all of the issued shares of Apicore until July 2017, as previously announced on July 3, 2014.\n\nAbout Apicore\n\nApicore is a leading process R&D and API manufacturing service provider for the worldwide pharmaceutical industry. Apicore offers a wide portfolio of services ranging from manufacture of API's for the generic industry to custom synthesis for early phase pharmaceutical research, and branded products. For more information, please visit Apicore online at www.apicore.com.\n\nAbout Medicure Inc.\n\nMedicure is a specialty pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. hospital market.  The primary focus of the Company and its subsidiaries is the marketing and distribution of AGGRASTAT (ti...